Dong‐Wook Kim

South Australian Health and Medical Research Institute — Australia

Medicine · Health Sciences

61h-index20.0kcitations599works8.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Myeloid Leukemia Treatments(358), Chronic Lymphocytic Leukemia Research(274), Acute Lymphoblastic Leukemia research(110), Eosinophilic Disorders and Syndromes(106), Acute Myeloid Leukemia Research(89)

Publications599 total

Long-Term Survival Gains after Allogeneic Hematopoietic Stem Cell Transplant are Driven by Reductions in Non-Relapse Mortality: A 35-Year Statewide Australian Cohort Study
Transplantation and Cellular Therapy·2026Open Access
Improved long-term tolerability with asciminib (ASC) vs investigator-selected (IS) tyrosine kinase inhibitors (TKIs) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Week 96 exploratory analysis of the phase 3 ASC4FIRST trial
Blood·2025
High-dose ponatinib in Korean CML and Ph+ ALL: real-world outcomes in early and heavily pretreated settings
Blood·2025Open Access
Asciminib (ASC) demonstrates continued improvement in patient-reported outcomes (PROs) vs investigator-selected tyrosine kinase inhibitors (IS-TKIs) in newly diagnosed chronic myeloid leukemia (CML): ASC4FIRST week 96 analysis
Blood·2025Open Access
Regulation of metabolic adaptation and leukemia progression by MUSASHI2-DEPTOR-KIF11 axis
Leukemia·2025· 1 cited
POSTER: CML-766 Primary Endpoint Results of the Phase 3b ASC4START Trial of Asciminib vs Nilotinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML-CP): Time to Treatment Discontinuation Due to Adverse Events (TTDAE)
Clinical Lymphoma Myeloma & Leukemia·2025
CML-575: ENABLE: A Phase 1a/1b Study of ELVN-001, a Selective Active Site Inhibitor of BCR::ABL1, in Patients With Previously Treated Chronic Myeloid Leukemia
Clinical Lymphoma Myeloma & Leukemia·2025
POSTER: CML-575 ENABLE: A Phase 1a/1b Study of ELVN-001, a Selective Active Site Inhibitor of BCR::ABL1, in Patients With Previously Treated Chronic Myeloid Leukemia
Clinical Lymphoma Myeloma & Leukemia·2025
CML-766: Primary Endpoint Results of the Phase 3b ASC4START Trial of Asciminib vs Nilotinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML-CP): Time to Treatment Discontinuation Due to Adverse Events (TTDAE)
Clinical Lymphoma Myeloma & Leukemia·2025
CML-754: Improved Patient-Reported Outcomes (PROs) With Asciminib vs Investigator-Selected Tyrosine Kinase Inhibitors (IS-TKIs) in Newly Diagnosed Chronic Myeloid Leukemia (CML): ASC4FIRST Week 48 PROs Analysis
Clinical Lymphoma Myeloma & Leukemia·2025· 1 cited
ORAL ABSTRACT: CML-575 ENABLE: A Phase 1a/1b Study of ELVN-001, a Selective Active Site Inhibitor of BCR::ABL1, in Patients With Previously Treated Chronic Myeloid Leukemia
Clinical Lymphoma Myeloma & Leukemia·2025
2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia
Leukemia·2025· 43 citedOpen Access
Primary endpoint results of the phase 3b ASC4START trial of asciminib (ASC) vs nilotinib (NIL) in newly diagnosed chronic phase chronic myeloid leukemia (CML-CP): Time to treatment discontinuation due to adverse events (TTDAE).
Journal of Clinical Oncology·2025· 1 cited
Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL
Blood Advances·2025· 6 citedOpen Access
KF1601, a dual inhibitor of BCR::ABL1 and FLT3, overcomes drug resistance in FLT3+ blast phase chronic myeloid leukemia
Molecular Cancer·2025· 1 citedOpen Access
Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: Phase 1 final results
Leukemia·2025· 9 citedOpen Access
Continuous manufacturing and process analytical technology: focusing on dosage forms with improved solubility and controlled release
Journal of Pharmaceutical Investigation·2025· 1 cited
Vodobatinib for patients with Philadelphia chromosome-positive chronic myeloid leukaemia resistant or intolerant to multiple lines of previous therapy: an open-label, multicentre, phase 1/2 trial
The Lancet Haematology·2025· 8 cited
Comparing Media and Law Enforcement Reports on Anti-Asian Hate Incidents During the COVID-19 Pandemic: Data Visualization Approach (Preprint)
2025Open Access
Novel Chip-Based Digital Real-Time PCR Platform with Lab on an Array for the Sensitive Detection of BCR::ABL1 Transcripts in Chronic Myeloid Leukemia
Blood·2024Open Access
page 1 of 30Next →

Frequent Co-authors

Jörge E. Cortes(26), Andreas Hochhaus(25), Timothy P. Hughes(22), Hagop M. Kantarjian(20), Carlo Gambacorti‐Passerini(13), Giuseppe Saglio(12), Susan Branford(11), Jane F. Apperley(10), H. Jean Khoury(10), Michele Baccarani(9), Philipp le Coutre(9), Charles Chuah(8), Martin C. Müller(8), Tim H. Brümmendorf(8), Jerald P. Radich(8), Ricardo Pasqüini(7), Richard A. Larson(7), Delphine Réa(7), Michael W. Deininger(7), Michael J. Mauro(7)